A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease
Open Access
- 1 January 2019
- journal article
- review article
- Published by FapUNIFESP (SciELO) in Revista Brasileira de Geriatria e Gerontologia
- Vol. 22 (4)
Abstract
Objective: To synthesize the available evidence and state of the art of economic evaluations which evaluate the use of memantine, whether alone or combined with donepezil, for moderate to severe Alzheimer’s disease (AD), focusing on the analytical decision models built. Method: The electronic databases MEDLINE, EMBASE, NHS EED, CEA Registry and LILACS were searched for references. After duplicates were removed, two independent reviewers evaluated the titles and abstracts and subsequently the full texts. The Drummond M. tool was used to evaluate the quality of the studies. Results: After the application of the eligibility criteria, twelve complete economic evaluations were included. One evaluation was a clinical trial, two involved simulations and nine used Markov models. The main outcome measure adopted was dominated by cost per quality adjusted life year (QALY). The use of memantine was considered cost-effective and dominant in eight studies; while in a single study, its use was dominated when compared to donepezil for moderate AD. Sensitivity analyzes were systematically performed, with robust results. The quality assessment indicated that the methodological quality of the studies was good. Conclusion: Although there is some controversy regarding the benefits derived from the use of memantine, whether combined or not with donepezil, the evidence collected suggests that it is cost-effective in the countries where the studies were performed. However, local economic studies need to be performed, given the significant variability derived from the different parameters adopted in the evaluations.Keywords
This publication has 37 references indexed in Scilit:
- Alzheimer's Disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological TreatmentCurrent Medicinal Chemistry, 2018
- Memantine for Alzheimer’s Disease: An Updated Systematic Review and Meta-analysisJournal of Alzheimer’s Disease, 2017
- Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysisPLOS ONE, 2017
- Impacto econômico da doença de Alzheimer no Brasil: é possível melhorar a assistência e reduzir custos?Ciencia & Saude Coletiva, 2014
- Health economic evaluation of treatments for Alzheimer′s disease: impact of new diagnostic criteriaJournal of Internal Medicine, 2014
- Panorama prospectivo das demências no Brasil: um enfoque demográficoCiencia & Saude Coletiva, 2013
- The global prevalence of dementia: A systematic review and metaanalysisAlzheimer's & Dementia, 2013
- A 24-week Randomized, Controlled Trial of Memantine in Patients With Moderate-to-severe Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 2007
- Memantine in Moderate-to-Severe Alzheimer's DiseaseNew England Journal of Medicine, 2003
- Memantine in severe dementia: results of the9M-best study (benefit and efficacy in severly demented patients during treatment with memantine)International Journal of Geriatric Psychiatry, 1999